4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-011213
CHIEF SCIENTIFIC OFFICER sold 5,000 shares at an average $16.07 ($80,366)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-04-21 | Sale : show line 1 in the form 10b5-1 | −4,670 | $16.03 | $74,848 | 998,018 | I |
| 2025-04-21 | Sale : show line 2 in the form 10b5-1 | −330 | $16.72 | $5,518 | 997,688 | I |
| Open-market sales · 5,000 sh · avg $16.07 · $80,366 | ||||||
Loading xslF345X05/form4-04232025_090427.xml…